GlassScriptPhysician profile
Leonard J Torok
NPI 1215088562
$5,941.80
in general payments reported to CMS, 2019-2025
27 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $893 · 2021: $357 · 2022: $741 · 2023: $780 · 2024: $1,013 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,923.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $708.71 | 2019-2025 | Otezla, Otezla, Enbrel |
| Abbvie INC. | $623.07 | 2019-2025 | Rinvoq |
| Sun Pharmaceutical Industries INC. | $560.63 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Leo Pharma INC. | $456.34 | 2020-2025 | Adbry, Anzupgo, Spevigo |
| Ucb, INC. | $452.34 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $434.90 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $428.21 | 2019-2025 | |
| Janssen Biotech, INC. | $388.89 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $300.50 | 2019-2025 | |
| Galderma Laboratories, L.P. | $290.71 | 2019-2024 | |
| Incyte Corporation | $261.49 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $245.96 | 2019-2025 | Zepbound, Taltz |
| Vyne Pharmaceuticals INC. | $167.38 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $146.33 | 2019-2024 | Cabtreo, Arazlo, Jublia |
| Pfizer INC. | $107.24 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $66.25 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.04 | 2022-2025 | Spevigo |
| Dermavant Sciences, INC. | $41.93 | 2023-2024 | Vtama |
| Epi Health, LLC | $34.97 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.32 | 2023-2025 | Sotyktu |
| Merck Sharp & Dohme LLC | $25.26 | 2023 | Keytruda |
| Biofrontera INC. | $23.02 | 2022 | |
| Revance Therapeutics, INC. | $21.36 | 2025 | Daxxify |
| Organogenesis INC. | $20.96 | 2021 | |
| Arcutis Biotherapeutics, INC. | $20.88 | 2024 | Zoryve |
| Celgene Corporation | $18.75 | 2019 | |
| Mayne Pharma Commercial LLC | $15.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Torok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.